Company: NewLink Genetics ($NLNK)
Based: Ames, IA
Raised: $43.4M (6.2M shares for $7)
Target range: 5.5M shares at $10 to $12
Current price: $6.48

Scoop: NewLink, a cancer vaccine developer, joins other biotechs on this list with no marketed products and little to no revenue. But the company was still able to pull off an IPO in November even though it had to cut its stock price to get the deal done. 

The company's pancreatic cancer vaccine HyperAcute Pancreas for surgically resected patients was featured in FierceBiotech's look at promising late-stage therapies for the disease. A late-stage trial of the drug in 700 Stage I and II patients is in progress, with full enrollment expected in 2013. HyperAcute Pancreas, which has gained fast track and orphan drug status, is also being studied as an adjuvant treatment for melanoma and lung cancer patients whose cancer has been surgically removed. NewLink was founded in 1999.